Hemispherx BioPharma, Inc (HEB) Sees Significant Decrease in Short Interest
Hemispherx BioPharma, Inc (NYSE:HEB) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totalling 782,505 shares, a decrease of 8.3% from the July 14th total of 853,780 shares. Based on an average daily volume of 171,110 shares, the short-interest ratio is presently 4.6 days. Approximately 2.8% of the company’s stock are short sold.
Shares of Hemispherx BioPharma (HEB) opened at 0.38 on Thursday. The firm has a 50-day moving average of $0.48 and a 200-day moving average of $0.54. The company’s market capitalization is $10.06 million. Hemispherx BioPharma has a 12 month low of $0.38 and a 12 month high of $2.64.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/hemispherx-biopharma-inc-heb-sees-significant-decrease-in-short-interest.html.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.